Letter

More on compulsory registration of clinical trials: GSK has created useful register

BMJ 2005; 330 doi: 10.1136/bmj.330.7489.479-b (Published 24 February 2005)
Cite this as: BMJ 2005;330:479.3

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Ronald Krall, senior vice president, Worldwide Development,
  2. Frank Rockhold (frank.w.rockhold@gsk.com), senior vice president, Biomedical Data Sciences
  1. GlaxoSmithKline, Upper Merion, PA 19087, USA

    EDITOR—The editorial by Abbasi and letters in response illustrate the considerable interest in the registration of clinical trials.1 2 As a pharmaceutical company that has created a register to communicate the results of clinical trials of our marketed products, GlaxoSmithKline would like to bring to your attention the decisions we have taken to make our register worthwhile and meaningful to the medical profession and …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular